{"denoms":[{"counts":[{"groupId":"BG000","value":"64"}],"units":"Participants"}],"groups":[{"description":"Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.","id":"BG000","title":"Bortezomib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"33","upperLimit":"76","value":"60"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"44"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Non-White"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"}]}],"title":"ISS Stage I"},{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"ISS Stage II"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"ISS Stage III"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Unknown"}],"description":"International Staging System (ISS) Stage I: serum ß2-M \\< 3.5 mg/L and serum albumin \\>/= 3.5 g/dL Stage II: Neither stage I nor stage III Stage III: serum ß2-M \\>/= 5.5 mg/L","paramType":"NUMBER","title":"ISS Stage","unitOfMeasure":"participants"}],"populationDescription":"The analysis population is comprised of eligible and treated participants."}